Draft Midterm Evaluation of the Fourth Cancer Control Plan

Overview

The 95th Cancer Control Promotion Council discussed a draft midterm evaluation report for the Fourth Cancer Control Promotion Basic Plan. Evaluation using a logic model showed certain overall achievements and improving trends, including declining cancer mortality and a higher proportion of cancer patients who felt they were living in a way true to themselves. Challenges included interpreting results affected by changes to patient experience survey questions, access to medical care and clinical trials, financial burdens, regional disparities, and the handling of qualitative information. The council confirmed a direction of reviewing indicators, data sources, target setting, and evaluation methods in the next plan while maintaining indicator continuity, and of advancing initiatives that reflect regional characteristics. The draft report is scheduled for publication in July 2026 after revisions are considered.

This summary was automatically generated by AI. Please refer to the original article for accuracy.

Key points

  • The 95th council meeting discussed a draft midterm evaluation report for the Fourth Plan.
  • Evaluation using a logic model showed certain overall achievements and improving trends.
  • Indicator limitations, financial burdens, and access to medical care and clinical trials emerged as challenges.
  • The report is scheduled for publication in July 2026.

Overview

The council was held in a hybrid format on June 18, 2026, and the draft midterm evaluation report for the Fourth Cancer Control Promotion Basic Plan was the main agenda item.

The draft report consists of four chapters: the purpose of the Fourth Plan, the purpose of the midterm evaluation, the midterm evaluation, and “Conclusion: Toward the Fifth Basic Plan,” organizing progress by field and future challenges.

The evaluation results organized progress and issues requiring additional action concerning cancer prevention, cancer care, living with cancer, and the infrastructure supporting them, with certain overall achievements and improving trends recognized.

Key figures

Council meeting date
June 18, 2026
Target cancer screening rate
60%
Proportion of cancer patients who felt they were living a self-directed daily life (baseline)
70.5%
Proportion of cancer patients who felt they were living a self-directed daily life (midterm measurement)
79.0%
Change in the proportion receiving recommended drugs after a cancer gene panel test
Decreased by 0.4 percentage points
Proportion of patients whose lives were affected by financial burdens (overall)
24.2%
Proportion of young cancer patients whose lives were affected by financial burdens
44.9%
Number of pediatric cancer pharmacotherapy specialists (from baseline to midterm measurement)
From 727 people to 721 people
Change in the number of companies registered for the Cancer Control Promotion Corporate Action
1.4 times

Impact

For patients and families, it will be important to improve access to second opinions before treatment, clinical trials, standard treatment, palliative care, and consultation support, and to identify and support financial and employment-related burdens.

Medical institutions and related academic societies and organizations will be expected to advance collaboration among hospitals, highly complex surgery, cancer genomic medicine, and the placement of specialized personnel while balancing standardization and centralization.

In policy management, it will be necessary to analyze the factors behind regional disparities and patient travel and treatment access, not only national figures, and to improve measures based on needs that are difficult to capture through quantitative indicators alone and on qualitative information.

Details

The evaluation presented a list of determinations for all indicators related to individual targets. For field-specific outcomes, it included all indicators, while for intermediate outcomes and outputs, it included core indicators and indicators rated C or showing a declining trend. Because the questionnaires and response options changed between the second and third patient experience surveys, the relevant indicators were marked with an asterisk and were not interpreted as simple improvement or decline.

Potential areas for addition or strengthening included individualized recommendations for cancer screening, recommendations to undergo cancer screening tailored to employment status, information on second opinions before treatment, sharing successful practices among prefectures, prompt collaboration between hospitals and clinics and among hospitals, access to clinical trials, standardization of expert panels, and nutritional therapy and rehabilitation for older adults.

Toward the Fifth Plan, the indicated direction was to reconsider the creation of indicators for items not yet established, the relationship between targets and measures in the logic model, data sources, evaluation methods for each indicator, and the setting of target values and certain standards, while ensuring continuity in indicators and evaluation methods during the Fourth Plan.

Committee members called for adding an explanation of the logic model to the report, increasing the implementation rate of routine HPV vaccination, addressing drug lags and drug loss, carefully evaluating the number of pediatric cancer specialists, and including economic and employment-related indicators, the use of AI, long-term follow-up, and basic palliative care.

Related Articles